EXO-CD24 by Nano24med for Acute Respiratory Distress Syndrome: Likelihood of Approval

EXO-CD24 is under clinical development by Nano24med and currently in Phase II for Acute Respiratory Distress Syndrome.

New molecular pathway identified for early onset coronary artery disease

A novel molecular pathway to explain how a mutation in the gene ACTA2 can cause individuals in their 30s – with normal cholesterol levels and

July 7, 2023

Gilead, Merck’s experimental long-acting HIV treatment heads to Phase 3

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

October 22, 2024

Fairy Tales and Sleep; Cognitive Impairment in AI

TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange,

December 29, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.